

Ampio Pharmaceuticals, Inc.
Form 8-K
January 10, 2017

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 7, 2017

AMPIO PHARMACEUTICALS, INC.

(Exact name of registrant as specified in Charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

001-35182
(Commission
File No.)
373 Inverness Parkway, Suite 200

26-0179592
(IRS Employer
Identification No.)

Edgar Filing: Ampio Pharmaceuticals, Inc. - Form 8-K

Englewood, Colorado 80112

(Address of principal executive offices, including zip code)

(720) 437-6500

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

Ampio Pharmaceuticals, Inc. (the Company) held its Annual Meeting of Stockholders on January 7, 2017. The number of shares of common stock entitled to vote at the annual meeting was 57,179,686. The number of shares of common stock present, in person or represented by proxy, and entitled to vote at the annual meeting was 40,310,393. All matters submitted to a vote of our stockholders at the annual meeting were approved and all director nominees were elected.

The certified results of each of the matters voted upon at the annual meeting, which are more fully described in our definitive proxy statement, are as follows:

(1) Election of five (5) directors for terms expiring at the 2017 annual meeting of stockholders.

| DIRECTORS | FOR | WITHHELD |
|-------------------------|------------|-----------|
| Michael Macaluso | 10,829,626 | 1,995,560 |
| David Bar-Or, M.D. | 10,777,922 | 2,047,264 |
| Philip H. Coelho | 11,090,701 | 1,734,485 |
| Richard B. Giles | 11,272,531 | 1,552,655 |
| David R. Stevens, Ph.D. | 11,279,586 | 1,545,600 |

There were 27,485,207 broker non-votes regarding this proposal.

(2) Ratification of the selection of EKS&H LLLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2016.

| FOR | AGAINST | ABSTAIN |
|------------|---------|---------|
| 39,445,732 | 275,533 | 589,128 |

There were no broker non-votes regarding this proposal.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMPIO PHARMACEUTICALS, INC.

By: /s/ Gregory A. Gould
Gregory A. Gould
Chief Financial Officer

Dated: January 10, 2017